The Readout Loud
321: Summit's upcoming cancer results, Recursion's mixed data, and the next big obesity target
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
We discuss the next big trend in obesity drug development — treatments that target the amylin hormone. Companies argue that these types of drugs could lead to less nausea and muscle loss, and the first big readout is coming later this year. We also chat about an upcoming presentation from Summit Therapeutics on its cancer drug that beat Merck’s Keytruda, mixed data from Recursion’s lead AI-derived drug candidate, and more news in the life sciences.